TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

about

Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease

P2860

Q58752270-E8A56F21-1162-423E-9873-1884515898FF

P2860

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

Item

http://www.wikidata.org/entity/Q47372528

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

@en

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

@nl

type

Item

label

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

@en

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

@nl

prefLabel

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

@en

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

@nl

P1476

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse

@en

P2093

Andrea Lorenzon

http://www.w3.org/2001/XMLSchema#string

Barbara Toffoli

http://www.w3.org/2001/XMLSchema#string

Bruno Fabris

http://www.w3.org/2001/XMLSchema#string

Fleur Bossi

http://www.w3.org/2001/XMLSchema#string

Giorgio Zauli

http://www.w3.org/2001/XMLSchema#string

Paola Secchiero

http://www.w3.org/2001/XMLSchema#string

Stefania Biffi

http://www.w3.org/2001/XMLSchema#string

Stella Bernardi

http://www.w3.org/2001/XMLSchema#string

P2860

Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes

Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1

PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis

Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions

PGC-1α, glucose metabolism and type 2 diabetes mellitus

Crosstalk between apoptosis, necrosis and autophagy

Mechanisms and metabolic implications of regional differences among fat depots

Regulation of lipid stores and metabolism by lipophagy

A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis

A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes

P304

69-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1042/CS20171221

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P50

Veronica Tisato

P577

2018-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29167318

http://www.w3.org/2001/XMLSchema#string

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

about

P2860

P2860

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698